TOTAL: $599.75M | ||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
Alnylam Pharmaceuticals Inc. (ALNY) | Exercised equity option | 0.066 | $1.15 | Alnylam received $1.15M in cash from partner Novartis AG due to Novartis' decision to exercise its option to purchase 65,922 unregistered Alnylam shares for $17.50 each (5/7) |
Amarin Corp. plc (UK; AMRN) | Private placement of convertible bridge loan notes | N/A | $2.6 | Amarin raised $2.6M in the placement; the notes mature on June 30 and pay an annual interest rate of 8 percent (5/26) |
Array BioPharma Inc. (ARRY) | Credit facility extension | N/A | $40 | Array received an additional $40M funding commitment from Deerfield Management, extending the commitment begun in 2008 to $120M (5/20) |
Bio-Rad Laboratories Inc. (NYSE:BIO) | Private placement of senior subordinated notes | N/A | $300 | Bio-Rad agreed to sell the 8% senior subordinated notes due 2016 (5/20) |
BioTime Inc. (OTC BB:BTIM) | Private placement of common stock | 2.2S and 2.2W | $4 | BioTime raised $4M through the placement of 2.2M shares and 2.2M warrants (5/14) |
Cell Therapeutics Inc. (CTIC) | Private placement of common stock and warrants | N/A | $20 | Cell Therapeutics sold $20M in shares at $1.25 each, plus warrants to purchase shares; Rodman & Renshaw LLC acted as exclusive placement agent (5/12) |
Cytokinetics Inc. (CYTK) | Private placement of common stock | 7.1S | $14 | Cytokinetics raised $14M in an offering of 7.1M shares priced at $1.97 each (5/19) |
Cytori Therapeutics Inc. (CYTX) | Private placement of stock and warrants | 1.86U | $4.2 | Cytori raised $4.2M through a private placement of 1.86M units, each consisting of one share and 1.75 five-year warants, with an exercise price of $2.62 each (5/8) |
Discovery Laboratories Inc. (DSCO) | Private placement of common stock and warrants | 14S and W | $11.3 | Discovery Labs raised $11.3M, placing 14M shares and warrants to purchase one-half share of stock for each share of common stock purchased; Lazard Capital Markets LLC acted as exclusive placement agent (5/11) |
Generex Biotechnology Corp. (GNBT) | Registered direct offering | N/A | $5 | Generex raised $5M through the offering of common stock to select accredited investors at 33 cents per share (5/20) |
GenVec Inc. (GNVC) | Registered offering | 9.6S and W for 9.6S | $6 | GenVec raised $6M in a registered offering of common stock and warrants (5/28) |
Haemacure Corp. (Canada; TSX:HAE) | Bridge loan | N/A | $2.5 | Haemacure entered into a term sheet with Angiotech Pharmaceuticals Inc. for a senior secured bridge loan of $2.5M (5/4) |
Hemispherx BioPharma Inc. (AMEX:HEB) | Private placement of common stock and Series A warrants | S and W for 6.1S | $18.3 | Hemispherx sold the shares for $1.10 each, a 20% discount; Rodman and Renshaw was the exclusive placement agent (5/11) |
Hemispherx BioPharma Inc. (AMEX:HEB) | Private placement of common stock and warrants | 11.9S and W for 4.16S | $16 | Hemispherx sold $16M in common stock and warrants in a registered offering to two institutional investors (5/19) |
Isolagen Inc. (AMEX:ILE) | Secured promissory notes and agreements | N/A | $0.5 | Isolagen entered into secured promissory notes and agreements with eight lenders to borrow $500,417 at an interest rate of 20% per annum (5/6) |
Kamada Ltd. (Israel; TASE: KMDA; PK:KAMAF | Private placement of common stock | 2.6S | $7 | Kamada raised $7M through the private allocation of 2.6M shares to a group of investors that includes board Chairman Ralf Hahn and UDT Med Holdings LLC (5/4) |
Kamada Ltd. (Israel; TASE: KMDA; PK:KAMAF) | Private placement | N/A | $1.5 | Kamada raised another $1.5M through a private placement with Meitav, an institutional investor in Israel (5/11) |
Oncolytics Biotech Inc. (Canada; ONCY) | Equity financing | 3.45U | $6 | Oncolytics entered an agreement with Bolder Investment Partners Inc. to buy 3.45M units at $2 per unit for gross proceeds of $6M (5/1) |
OncoMethylome Sciences SA (Belgium; BR:ONCOB) | Warrant exercise | 0.0245S | €0.11 ($0.156) |
OncoMethylome raised $155,569 as a result of the exercise of warrants (5/29) |
Oncothyreon Inc. (ONTY) | Private placement of common stock and warrants | 3.88S and W for 2.91S | $11.1 | Oncothyreon raised $11.1M through the sale (5/20) |
PolyMedix Inc. (OTC BB:PYMX) | Equity line facility | N/A | $10 | PolyMedix entered into an agreement with Dutchess Equity Fund LP for up to $10M of financing through an equity line facility (5/21) |
Rexahn Pharmaceuticals Inc. (AMEX:RNN) | Private placement of common stock and warrants | 2.9S and W for 5.6S | $10 | Rexahn sold the stock and warrants to a single institutional investor (5/20) |
SemBioSys Genetics Inc. (Canada; TSX:SBS) | Loan | N/A | $1.5 | SemBioSys reached an agreement with AVAC Ltd.for a $1.5M loan, repayable within 18 months (5/4) |
Spectrum Pharmaceuticals Inc. (SPPI) | Registered direct offering | 3.9S and W for 1.96S | $20 | Spectrum received commitments from Federated Kaufmann Fund and two other institutional investors; Rodman & Renshaw LLC acted as the exclusive placement agent (5/27) |
Synairgen plc (UK; LSE:SNG) | Private placement of common stock | 29.5S | £6.35 ($10.2) |
Synairgen raised $10.2M through institutional investors (5/29) |
ThromboGenics NV (Belgium; BR:THR) | Exercise of warrants | N/A | €3.1 ($4.1) |
ThromboGenics raised $4.1M through the exercise of warrants by its employees (5/7) |
Unigene Laboratories Inc. (OTC BB:UGNE) | Private placement | 0.375S | $5 | Unigene drew down $5M under its agreement with Victory Park Management LLC in exchange for 375,000 shares (5/29) |
Vernalis plc (UK; LSE:VER) | Private placement | 799S | £22.1 ($36.9) |
Vernalis raised $36.9M offering 799M shares at 3 pence each, a 25.9% discount (5/5) |
Vical Inc. (VICL) | Registered direct offering | 6.7S | $20 | Vical raised $15.4M in an offering of 6.7M shares of common stock and options to buy up to 3.3M additional shares (5/22); Vical received a commitment from Special Situations Funds to buy about $4.6M of securities on the same terms; it will sell 2M shares of common stock and option to buy up to 1M additional shares (5/26) |
Vicor Technologies Inc. (OTC BB:VCRT) | Private placement of 8% convertible notes | N/A | $0.74 | Vicor raised $740,000 through the sale of notes due in 2011 (5/7) |
XOMA Ltd. (XOMA) | Private placement of units | 11.8U | $10 | XOMA raised $10M through the sale of 11.8M units, each comprising one common share and a warrant to purchase half a common share (5/15) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange; @ Refers to the date of the press release. ** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed.AMEX = American Stock Exchange; BR = Brussels Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TASE = Tel Aviv Stock Exchange; TSX = Toronto Stock Exchange. |